Novo Nordisk has 'plan B' in place as regulators examine Catalent deal
Novo Nordisk says it has a “plan B” in place to scale up production in the event that its parent’s acquisition of US contract drug manufacturer Catalent is blocked by regulators....To view the full article, register now.
Already a subscriber? Click here to view full article